Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Four-factor prothrombin complex concentrate (4F-PCC) is a biologic, plasma-derived blood product containing the four vitamin K-dependent coagulation factors: Factor II (prothrombin), Factor VII, Factor IX, and Factor X, along with anticoagulant proteins C and S. It is primarily used for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (e.g., warfarin) therapy in adult patients with acute major bleeding or those needing urgent surgery or invasive procedures. Unlike three-factor PCCs, 4F-PCC contains therapeutic amounts of Factor VII, allowing for more rapid and effective normalization of the International Normalized Ratio (INR). Marketed under brand names such as Kcentra and Beriplex, it acts by directly replacing the depleted clotting factors, bypassing the need for vitamin K-mediated synthesis which takes significantly longer. In clinical practice, it is often preferred over fresh frozen plasma (FFP) due to its smaller infusion volume, faster administration, and lack of requirement for blood type matching.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on prothrombin complex concentrate.